EXTRACTS Hedera helix – folium

Hedera helix –
folium
D EXTRACTS
FROM GERMANY
Anklam Extrakt GmbH
Impressum
Johann-Friedrich-Böttger-Strasse 4
Anklam Extrakt GmbH
17389 Anklam
Johann-Friedrich-Böttger-Strasse 4
Efeublätter
Ivy leaves
17389 Anklam/Germany
Sales office
Ytterbium 4
Court of registration: Stralsund
91058 Erlangen/Germany
Registry number: HRB 7217
[email protected]
Sales tax identification number
www.anklam-extrakt.com
according to § 27a UStG: DE254700277
Visit our
homepage:
Managing directors responsible for content:
Claudia Pühn, Vahe Pekmez, Klaus Schekahn
General information
Six European species of ivy belong to the genus Hedera in the
ginseng family (Araliaceae). Common or English ivy, Hedera
helix L. is a climbing, evergreen, woody plant found growing
on trees, walls, rocks and along the ground in Europe and
Asia as well as in North and South America. Small aerial roots
allow the plants to adhere to many surfaces.
In autumn, ivy plants bear yellow or greenish-yellow round
flowers in clusters. During winter, the small, dark purple,
black, or yellow fruits develop.
For commercial use, the plant material derives from wildcrafting. The main collection areas are in Eastern and
South-Eastern Europe.
The shiny or leathery leaves are highly polymorphic, appearing in different shapes and sizes, and containing different
active constituents. More than 500 varieties of ivy are
known, most of which are used for ornamental purposes.
Anklam Extrakt acquires its plant raw materials from areas
that are famous for high levels of active ingredient levels and
with the assistance of experienced collectors.
Use as a food
Extract qualities
No known use as a food.
The powdered extract of ivy leaves (Hedera helix folia) is
produced from the herbal drug using an aqueous-ethanolic
mixture as extraction solvent. Our extract quality complies
with the requirements of the Ph. Eur. monograph.
Assay: Hedeacoside C content is more than 10 % calculated
to the dried extract and is analyzed with a validated HPLC
method.
Feel free to contact us regarding documentation to support
your regulatory process (up to an ASMF including stability
report).
Hederae e fol extr spir sicc - 00-115-0541-00
Ivy Leaf Powdered Extract
DER 6–7:1 / Extraction solvent Ethanol 40 %
90 % native extract, 10 % maltodextrin
Hederae e fol extr spir sicc - 00-115-0541-01
Ivy Leaf Powdered Extract
DER 4–8:1 / Extraction solvent Ethanol 30 %
100 % native extract
Functional properties
Constituents
Common ivy is known for its pharmacological active
saponins which have anti-inflammatory, antiviral, antibacterial, antimycotic, and anthelmintic effects in animals.
The most important constituents of the common
ivy leaves are:
These compounds are stated to possess secretolytic,
expectorant, antitussive, and spasmolytic action. Human
medical applications have focussed on its spasmolytic
action. Coughs and bronchitis are the most important indications.
Average daily dose
0.3–0.8 g of ivy leaves or preparations thereof.
Acc. to ESCOP: Oral use of ethanolic preparations:
Adults: 250–420 mg.
Children 4–12 yo 150–210 mg, 1–4 yo 50–150 mg,
0–1 yo 20–50 mg.
• 2.5–6 % mostly bidesmosidic triterpene saponins
with hederagenin, oleanolic acid and bayogenin as
aglycones and acylglycosidic sugar chains
• Small amounts of monodesmosides such as α-hederin
and hederagenin-3-O-ß-D-glucoside
• Primarily hederasaponin C (hederacoside C) together
with other hederasaponins
• Flavonoids such as quercetin and kaempferol including
their 3-O-rutinosides and 3-O-glucosides (= isoquercitrin
and astragalin)
• Caffeic acid derivates and other phenolic acids
• Coumarin glycoside scopolin and the polyacetylenes
falcarinone, falcarinol and 11, 12-dihydrofalcarinol
• Phytosterols as stigmasterol, sitosterol, cholesterol,
campesterol, α-spinasterol
Literature
1. Buechi S, Kaehler D. Efeu (Hedera helix) bei Atemwegserkrankungen.
Schweiz. Zschr. GanzheitsMedizin 15 (2003), 124–128.
2. Demirci B, Goppel M, Demirci F, Franz G, HPLC profiling and quantification of active principles in leaves of Hedera helix L. Pharmazie 59
(2004), 770–774.
3. European Medicines Agency, COMMITTEE ON HERBAL MEDICINAL
PRODUCTS (HMPC) DRAFT ASSESSMENT REPORT ON HEDERA HELIX L.
FOLIUM, Doc. Ref.: EMA/HMPC/289432/2009.
4. Gladtke E: Zur Wirksamkeit eines Efeublätterpräparates (Prospan).
Intern Praxis 32 (1992), 187.
5. Horz KH, Reichling J (2003). Hedera. In: HagerROM, Springer Verlag,
Heidelberg.
6. Schilcher H, Kammerer S, Wegener T. (2007). Leitfaden Phytotherapie,
Urban&Fischer, 3. Auflage, München.
7. Trute A, Gross J, Mutschler E, Nahrstedt A: In vitro antispasmodic
compounds of the dry extract obtained from Hedera helix. Planta Med 63
(1997), 125–129.
8. Trute A, Nahrstedt A: Identification and quantitative analysis of phenolic
dry extracts of Hedera helix. Planta Med 63 (1997), 177–179.
9. Wagner H, Reger H. Folium Hederae-Extrakte. Dtsch Apoth Ztg
126 (1986), 2613–2617.
10. Wichtl M (2002) Hedera folium. In: Teedrogen und Phytopharmaka.
Wissenschaftliche Verlagsgesellschaft mbH, 4. Auflage, Stuttgart.
Monographs: ESCOP; Commission E
Disclaimer
The content of this brochure is based on our findings and experience.
Our goal is to inform our customers to the best of our current knowledge.
The information is, however, non-binding. Rights of third parties must
be observed. The recommended dosages are only guidelines and cannot
replace preliminary trials with individual products. Furthermore, before
sale, it is essential that all products satisfy local legal requirements.
A
B
C
D
E
// Images upper left to lower right
A. Pilot plant allows sample production on a small scale
B. Vacuum belt dryer in use
C. Qualified and motivated staff
D. Tailor-made plant extracts
E. The inside of a vacuum belt dryer